

Supplemental Tables for:

Utility of the Geriatric 8 for the prediction of therapy-related toxicity in older adults with diffuse large B-cell lymphoma
Shin Lee et al.

Supplementary table 1. Multivariate logistic regression analysis for clinical factors associated with the occurrence of febrile neutropenia

	IPI		IPI factors	
	OR (95% CI)	<i>P</i> value	OR (95% CI)	<i>P</i> value
Male sex	1.290 (0.840–1.980)	0.245	1.270 (0.821–1.960)	0.284
IPI score	1.240 (1.010–1.530)	0.043		
Age			0.985 (0.948–1.020)	0.417
ECOG PS ≥ 2			1.700 (0.978–2.970)	0.060
LDH >ULN			0.974 (0.581–1.630)	0.919
Stage ≥ 3			1.140 (0.651–1.980)	0.653
Extranodal sites ≥ 2			1.390 (0.851–2.270)	0.188
Serum albumin (g/dL)	0.990 (0.703–1.390)	0.952	0.997 (0.705–1.410)	0.985
Bulky mass	1.790 (1.050–3.040)	0.032	1.730 (1.010–2.980)	0.047
Total ARDI	1.010 (1.000–1.020)	0.026	1.010 (1.000–1.020)	0.035
G8 score (/point)	0.897 (0.827–0.972)	0.008	0.896 (0.819–0.980)	0.017
CCI score (/point)	1.150 (0.997–1.310)	0.054	1.130 (0.987–1.300)	0.075

ARDI, average relative dose intensity; CCI, Charlson Comorbidity Index; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; G8, Geriatric 8; IPI, International Prognostic Index; LDH, lactate dehydrogenase; OR, odds ratio; ULN, upper limit of normal

Supplementary table 2. Multivariate logistic regression analysis for clinical factors associated with the occurrence of severe non-hematological toxicities

	IPI		IPI factors	
	OR (95% CI)	<i>P</i> value	OR (95% CI)	<i>P</i> value
Male sex	1.340 (0.855–2.110)	0.200	1.260 (0.796–1.990)	0.323
IPI score	1.180 (0.946–1.470)	0.143		
Age			0.970 (0.933–1.010)	0.125
ECOG PS \geq 2			0.883 (0.496–1.570)	0.672
LDH >ULN			0.760 (0.434–1.330)	0.336
Stage \geq 3			1.500 (0.806–2.800)	0.200
Extranodal sites \geq 2			1.640 (0.985–2.720)	0.057
Serum albumin (g/dL)	0.686 (0.478–0.985)	0.044	0.686 (0.475–0.991)	0.044
Bulky mass	1.830 (1.070–3.140)	0.027	1.710 (0.986–2.970)	0.056
Total ARDI	0.993 (0.986–1.000)	0.077	0.991 (0.984–0.999)	0.033
G8 score (/point)	0.917 (0.843–0.996)	0.041	0.873 (0.794–0.960)	0.005
CCI score (/point)	1.050 (0.910–1.200)	0.525	1.040 (0.905–1.200)	0.560

ARDI, average relative dose intensity; CCI, Charlson Comorbidity Index; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; G8, Geriatric 8; IPI, International Prognostic Index; LDH, lactate dehydrogenase; OR, odds ratio; ULN, upper limit of normal

Supplementary table 3. Multivariate logistic regression analysis for clinical factors associated with the occurrence of severe adverse events

	IPI		IPI factors	
	OR (95% CI)	<i>P</i> value	OR (95% CI)	<i>P</i> value
Male sex	1.110 (0.714–1.720)	0.649	1.050 (0.669–1.640)	0.841
IPI score	1.150 (0.932–1.410)	0.194		
Age			0.972 (0.935–1.010)	0.167
ECOG PS \geq 2			1.880 (1.040–3.400)	0.038
LDH >ULN			0.657 (0.386–1.120)	0.122
Stage \geq 3			1.000 (0.572–1.760)	0.994
Extranodal sites \geq 2			1.700 (1.000–2.890)	0.049
Serum albumin (g/dL)	0.690 (0.479–0.994)	0.047	0.692 (0.477–1.000)	0.053
Bulky mass	1.910 (1.060–3.460)	0.318	1.830 (0.997–3.380)	0.051
Total ARDI	1.000 (0.996–1.010)	0.380	1.000 (0.996–1.010)	0.409
Modified-G8 score (/point)	0.908 (0.829–0.995)	0.038	0.892 (0.806–0.987)	0.046
CCI score (/point)	1.190 (1.020–1.380)	0.024	1.120 (0.961–1.300)	0.147

ARDI, average relative dose intensity; CCI, Charlson Comorbidity Index; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; G8, Geriatric 8; IPI, International Prognostic Index; LDH, lactate dehydrogenase; OR, odds ratio; ULN, upper limit of normal